Redcare Pharmacy NV (SHPPF) Fair Value & Analysis
Healthcare · US · Market cap $1.3B
Redcare Pharmacy NV
SHPPF · US
Fair value as of: Jun 24, 2026
From 3 valuation models · updated 12 days ago
Fair value updated Jun 24, 2026 — revised from $143.56 to $142.58 (−0.7%) since Jun 23, 2026. Share price +43.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $45.18 – $148.22 · fair‑value band $106.93 – $178.22 · the $64.80 price screens below the $142.58 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Redcare Pharmacy NV (SHPPF) currently trades at $64.80, while our model-based Fair Value estimate is $142.58 — implying the stock looks roughly 120.0% undervalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Redcare Pharmacy NV generated revenue of $3.1B at a net margin of -1.2%. Revenue grew 18.4% year over year. It earns a return on equity of -8.1%. Net debt stands at $323M. Fundamentals as of Jun 24, 2026
Our scenario range runs from $106.93 (bear case) to $178.22 (bull case); at $64.80, the current price sits below that range. The share trades about 56% below its 52-week high and 43% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside — at 120%, SHPPF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Redcare Pharmacy NV operates the online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. It offers prescription and non-prescription over-the-counter pharmaceuticals, beauty and personal care products, and food supplements. The company was formerly known as Shop Apotheke Europe N.V. and changed its name to Redcare Pharmacy NV in June 2023. Redcare Pharmacy NV was founded in 2001 and is based in Sevenum, the Netherlands.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Redcare Pharmacy NV reported revenue of $2.9B in FY2025 versus $1.1B in FY2021, a compound +29.0%/yr. Reported net income was −$37.7M in FY2025.
Is SHPPF fairly valued? → Check now
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIY | $4.26 | $6.93 | +63% |
| Alibaba Health Information Technology Limited ALBBY | $8.42 | $6.94 | -18% |
| Raia Drogasil S.A RADL3 | R$17.76 | R$14.97 | -16% |
| Yifeng Pharmacy Chain Co 603939 | ¥19.75 | ¥40.59 | +106% |
| Clicks Group CLCGY | $27.97 | $34.29 | +23% |
| Sugi Holdings SGIPF | $16.29 | $32.19 | +98% |
| Corporativo Fragua, S.A. CGSBF | $29.66 | $40.13 | +35% |
| DaShenLin Pharmaceutical Group 603233 | ¥15.87 | ¥26.45 | +67% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.74 | ¥11.45 | -2% |
| MedPlus Health Services Limited MEDPLUS | ₹816.95 | ₹393.38 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Redcare Pharmacy NV (SHPPF) undervalued?
What is the fair value of SHPPF?
What is the quality score of SHPPF?
What is the revenue of Redcare Pharmacy NV (SHPPF)?
What is the net profit margin of SHPPF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.